肠促胰岛素类药物与胆管癌风险:斯堪的纳维亚队列研究
该研究利用瑞典、丹麦和挪威2007-2018年全国登记数据,开展两项活性对照队列研究,分别比较DPP4抑制剂或GLP-1受体激动剂与磺脲类药物的胆管癌发生风险。主要分析显示,DPP4抑制剂相比磺脲类的调整HR为1.15(95%CI 0.90-1.46),GLP-1受体激动剂为1.25(95%CI 0.89-1.76),均无统计学显著升高。
要点
- DPP4抑制剂使用与胆管癌风险无显著增加(调整HR 1.15,95%CI 0.90-1.46)。
- GLP-1受体激动剂使用与胆管癌风险无显著增加(调整HR 1.25,95%CI 0.89-1.76)。
- 两种药物绝对风险差异均为每10万人年3例事件,置信区间包含0。
核心结论
- 在三国全国性数据中,使用DPP4抑制剂或GLP-1受体激动剂相比磺脲类药物,未与胆管癌风险显著增加相关。
研究设计与样本
- 基于瑞典、丹麦和挪威2007-2018年全国登记数据的两项活性对照队列研究,分别比较DPP4抑制剂 vs 磺脲类和GLP-1受体激动剂 vs 磺脲类。
- 采用Cox回归模型调整潜在混杂因素,从治疗开始后第366天起估计风险比以考虑癌症潜伏期。
主要发现
- DPP4抑制剂主分析纳入222,577例患者(中位随访4.5年)和123,908例磺脲类患者(中位随访5.1年),发生350例胆管癌事件。
- DPP4抑制剂 vs 磺脲类的胆管癌发病率26 vs 23/10万人年,调整HR 1.15(95%CI 0.90-1.46),绝对率差3(95%CI -3至10)例/10万人年。
- GLP-1受体激动剂主分析纳入96,813例患者(中位随访4.4年)和142,578例磺脲类患者(中位随访5.5年),发生249例胆管癌事件。
- GLP-1受体激动剂 vs 磺脲类的胆管癌发病率26 vs 23/10万人年,调整HR 1.25(95%CI 0.89-1.76),绝对率差3(95%CI -5至13)例/10万人年。
临床怎么用
- 临床使用DPP4抑制剂或GLP-1受体激动剂时,无需因胆管癌风险担忧而改变处方决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Concerns have been raised regarding a potential association of use of the incretin-based drugs dipeptidyl peptidase 4 (DPP4) inhibitors and glucagon-like peptide-1 (GLP-1)-receptor agonists with risk of cholangiocarcinoma. We examined this association in nationwide data from three countries. METHODS: We used data from nationwide registers in Sweden, Denmark and Norway, 2007-2018, to conduct two cohort studies, one for DPP4 inhibitors and one for GLP-1-receptor agonists, to investigate the risk of incident cholangiocarcinoma compared with an active-comparator drug class (sulfonylureas). The cohorts included patients initiating treatment episodes with DPP4 inhibitors vs sulfonylureas, and GLP-1-receptor agonists vs sulfonylureas. We used Cox regression models, adjusted for potential confounders, to estimate hazard ratios from day 366 after treatment initiation to account for cancer latency. RESULTS: The main analyses of DPP4 inhibitors included 1,414,144 person-years of follow-up from 222,577 patients receiving DPP4 inhibitors (median [IQR] follow-up time, 4.5 [2.6-7.0] years) and 123,908 patients receiving sulfonylureas (median [IQR] follow-up time, 5.1 [2.9-7.8] years) during which 350 cholangiocarcinoma events occurred. Use of DPP4 inhibitors, compared with sulfonylureas, was not associated with a statistically significant increase in risk of cholangiocarcinoma (incidence rate 26 vs 23 per 100,000 person-years; adjusted HR, 1.15 [95% CI 0.90, 1.46]; absolute rate difference 3 [95% CI -3, 10] events per 100,000 person-years). The main analyses of GLP-1-receptor agonists included 1,036,587 person-years of follow-up from 96,813 patients receiving GLP-1-receptor agonists (median [IQR] follow-up time, 4.4 [2.4-6.9] years) and 142,578 patients receiving sulfonylureas (median [IQR] follow-up time, 5.5 [3.2-8.1] years) during which 249 cholangiocarcinoma events occurred. Use of GLP-1-receptor agonists was not associated with a statistically significant increase in risk of cholangiocarcinoma (incidence rate 26 vs 23 per 100,000 person-years; adjusted HR, 1.25 [95% CI 0.89, 1.76]; absolute rate difference 3 [95% CI -5, 13] events per 100,000 patient-years). CONCLUSIONS/INTERPRETATION: In this analysis using nationwide data from three countries, use of DPP4 inhibitors and GLP-1-receptor agonists, compared with sulfonylureas, was not associated with a significantly increased risk of cholangiocarcinoma.
引用
- Ueda P, Wintzell V, Melbye M, et al. Use of incretin-based drugs and risk of cholangiocarcinoma: Scandinavian cohort study. Diabetologia. 2021. PMID: 34254177. doi:10.1007/s00125-021-05508-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。